Now is a critical moment for all involved in caring for cancer patients to engage in this national policy debate; numerous cancer advocacy organizations have already joined the effort to oppose the sequester cuts to oncology drugs.
Michael Diaz, MD
Advertisement
Articles by Michael Diaz, MD
Advertisement
Latest Updated Articles
How the Sequester Cuts Are Harming OncologyMay 15th 2013
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC
2
FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer
3
FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer
4
Experts Analyze 6-Year Zanubrutinib Data Across CLL/SLL Settings
5